Squarepoint
MREO

Squarepoint’s Mereo BioPharma MREO Stock Holding History

Squarepoint’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,055
Closed -$61.9K – 4655
2025
Q3 		$61.9K Buy
30,055
+9,387
+45% +$17.3K ﹤0.01% 4196
2025
Q2 		$56K Buy
20,668
+2,737
+15% +$6.61K ﹤0.01% 4289
2025
Q1 		$40.3K Sell
17,931
-5,736
-24% -$16.2K ﹤0.01% 4376
2024
Q4 		$82.8K Buy
23,667
+2,842
+14% +$11.2K ﹤0.01% 4744
2024
Q3 		$85.6K Sell
20,825
-6,472
-24% -$26.8K ﹤0.01% 3904
2024
Q2 		$98.3K Sell
27,297
-20,390
-43% -$66K ﹤0.01% 3805
2024
Q1 		$157K Buy
+47,687
New +$161K ﹤0.01% 3692
2021
Q2 		– Sell
-17,699
Closed -$60K – 3526
2021
Q1 		$60K Buy
+17,699
New +$62.6K ﹤0.01% 2976

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Squarepoint's MREO Position: Q4 2025 in Review

Squarepoint sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 30,055 shares — an estimated $61.9K sold.

Squarepoint first reported a position in MREO in Q1 2021 and held it in 8 quarters. The position peaked at $157K in Q1 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Squarepoint reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 30,055 Mereo BioPharma shares in Q4 2025, an estimated $61.9K.
  • Squarepoint first reported a position in Mereo BioPharma in Q1 2021 and held it in 8 quarters.
  • Squarepoint's Mereo BioPharma position peaked at $157K in Q1 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.